In a filing, Kymera Therapeutics Inc revealed its Director Booth Bruce unloaded Company’s shares for reported $2.9 million on Mar 15 ’24. In the deal valued at $40.46 per share,71,764 shares were sold. As a result of this transaction, Booth Bruce now holds 806,697 shares worth roughly $31.86 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Booth Bruce sold 55,779 shares, generating $2,229,927 in total proceeds. Upon selling the shares at $39.98, the Director now owns 819,151 shares.
Before that, Booth Bruce sold 139,255 shares. Kymera Therapeutics Inc shares valued at $5,880,415 were divested by the Director at a price of $42.23 per share. As a result of the transaction, Booth Bruce now holds 828,830 shares, worth roughly $32.73 million.
Wolfe Research initiated its Kymera Therapeutics Inc [KYMR] rating to a Peer perform in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who increased its forecast for the stock in early January from “a Neutral” to “an Overweight”. BofA Securities also remained covering KYMR and has decreased its forecast on January 03, 2024 with a “Neutral” recommendation from previously “Buy” rating. Wells Fargo revised its rating on December 19, 2023. It rated KYMR as “an Equal weight” which previously was an “an Overweight”.
Price Performance Review of KYMR
On Tuesday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -0.03% to $39.49. Over the last five days, the stock has lost -0.20%. Kymera Therapeutics Inc shares have risen nearly 55.11% since the year began. Nevertheless, the stocks have risen 34.64% over the past one year. While a 52-week high of $45.31 was reached on 02/27/24, a 52-week low of $9.60 was recorded on 01/04/24. SMA at 50 days reached $37.20, while 200 days put it at $24.29. A total of 0.38 million shares were traded, compared to the trading of 0.32 million shares in the previous session.
Levels Of Support And Resistance For KYMR Stock
The 24-hour chart illustrates a support level at 38.87, which if violated will result in even more drops to 38.24. On the upside, there is a resistance level at 40.24. A further resistance level may holdings at 40.98. The Relative Strength Index (RSI) on the 14-day chart is 48.72, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.99, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.50%. Stochastics %K at 21.05% indicates the stock is a holding.
How much short interest is there in Kymera Therapeutics Inc?
A steep rise in short interest was recorded in Kymera Therapeutics Inc stocks on Feb 29, 2024, dropping by 10000.0 shares to a total of 8.25 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 8.26 million shares. There was a decline of -0.12%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 15.12% of the overall stock float, the days-to-cover ratio (short ratio) fell to 12.06.
The most recent change occurred on June 30, 2023 when Truist began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.
